Skip to content

Palvella Therapeutics

US · PVLA #2822 by market cap Listed 1970
142.85 -2.92 -2.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    William Blair Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $266
    Market Newswire · 2026/10/16
  • Rating change
    Cantor Fitzgerald Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210
    Market Newswire · 2026/10/22
  • Rating change
    H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Cuts Target Price to $246
    Market Newswire · 2026/10/12
  • Clear Street Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $220
    Market Newswire · 2026/10/21
  • Rating change
    LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $225
    Market Newswire · 2026/7/22
  • A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $246
    Market Newswire · 2026/11/7
  • Rating change
    H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $246
    Market Newswire · 2026/10/20
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/10/12
  • CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $243
    Market Newswire · 2026/11/9
  • Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Cuts Target Price to $232
    Market Newswire · 2026/10/29
  • Palvella Therapeutics (PVLA.US) will release its financial report before the market opens on November 5.
    Market Newswire · 2026/10/31
  • Rating change
    H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270
    Market Newswire · 2026/8/6
  • Rating change
    Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $240
    Market Newswire · 2026/9/21
  • Rating change
    Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207
    Market Newswire · 2026/8/5
  • Rating change
    A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $267
    Market Newswire · 2026/8/5
  • Rating change
    Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210
    Market Newswire · 2026/8/5
  • Rating change
    Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240
    Market Newswire · 2026/9/10
  • Rating change
    BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215
    Market Newswire · 2026/10/13
  • Rating change
    Raymond James Maintains Palvella Therapeutics(PVLA.US) With Buy Rating
    Market Newswire · 2026/10/16
  • Rating change
    TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267
    Market Newswire · 2026/7/22
  • Rating change
    Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)
    TipRanks · 2026/7/1
  • Rating change
    CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227
    Market Newswire · 2026/6/25
  • Rating change
    Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250
    Market Newswire · 2026/6/24
  • Form 144 | Palvella Therapeutics(PVLA.US) Director Proposes to Sell 3.7 Million in Common Stocks
    Market Newswire · 2026/10/14
  • Rating change
    A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $210 to $270
    Market Newswire · 2026/5/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Palvella Therapeutics discussion 0 comments

Add a comment